Bayer & Janssen v. Biocon Pharma: XARELTO® Patents Dismissed with Prejudice
Bayer AG, Bayer Pharma AG, and Janssen Pharmaceuticals filed suit in Delaware District Court against Biocon Pharma entities alleging infringement of two patents covering rivaroxaban tablets sold as XARELTO®. The case resolved in just 136 days, with all claims and counterclaims dismissed with prejudice under a bilateral stipulation.
XARELTO® Generic Entry Challenged and Resolved Inside Five Months
On 24 March 2023, Bayer AG, Bayer Pharma AG, and Janssen Pharmaceuticals, Inc. filed suit in the District of Delaware against Biocon Pharma Ltd., Biocon Pharma, Inc., and Biocon Limited, asserting infringement of US9539218B2 and US10828310B2. Both patents relate to rivaroxaban — the active pharmaceutical ingredient in XARELTO® — specifically covering 2.5 mg, 10 mg, 15 mg, and 20 mg tablet formulations. The action was assigned to Judge Richard G. Andrews.
The case closed on 7 August 2023, 136 days after filing. The recorded basis of termination is Dismissed with Prejudice. The docket order states that, pursuant to Federal Rules of Civil Procedure 41(a)(1) and 41(c), all parties filed a bilateral stipulation of dismissal: plaintiffs' claims against Biocon and Biocon's counterclaims against plaintiffs were both dismissed with prejudice, with each party bearing its own costs, disbursements, and attorneys' fees. The specific terms underlying the stipulation are not disclosed in the available record.
A resolution in 136 days — before any claim construction hearing would typically be scheduled in Delaware — suggests the parties reached an agreement early in the litigation lifecycle, though the basis for that agreement is not public. The mutual dismissal with prejudice, covering all claims and defenses on both sides, closes off re-litigation of these specific disputes between these parties. What drove the early resolution, and whether any commercial arrangement was reached outside the public record, cannot be determined from the available case documents.
See Complete Case & Patent Analysis →Filing to Dismissed with Prejudice in 136 days
136 days — well below average for pharmaceutical patent disputes in Delaware
US9539218B2 & US10828310B2 — Rivaroxaban Tablet Formulations (XARELTO®)
Any pharmaceutical company, CDMO, or ANDA filer developing rivaroxaban tablet products — at any of the four commercial dose strengths — should treat these two patents as live FTO risks. The dismissal of this case with prejudice produced no invalidity findings and no claim narrowing, meaning both patents stand in their full issued scope. Companies that have already filed Paragraph IV certifications, or are preparing to do so, face the same claim landscape that Biocon faced at the outset of this litigation.
Official order — verbatim text
The stipulated dismissal is bilateral and comprehensive — it extinguishes all claims and counterclaims of all named parties with prejudice. The explicit inclusion of 'all claims and defenses asserted by Biocon against Plaintiffs' is notable: it closes off Biocon's invalidity and non-infringement positions, not merely the plaintiffs' infringement case. Each party bearing its own fees indicates neither side extracted a cost-shifting concession under 35 U.S.C. § 285.
Dismissed with prejudice: what the bilateral stipulation means for both parties
Bilateral Rule 41 stipulated dismissal with prejudice
Under FRCP 41(a)(1) and 41(c), both sides jointly stipulated to dismiss all claims and counterclaims with prejudice. A dismissal with prejudice is a final adjudication on the merits, meaning neither party may re-file the same claims in federal court. The bilateral structure — covering plaintiffs' infringement claims and Biocon's defenses/counterclaims simultaneously — is characteristic of a fully resolved dispute rather than a one-sided withdrawal.
Final, court-entered, no re-filingInfringement claims closed; patents remain in force
The dismissal with prejudice ends Bayer and Janssen's infringement claims against Biocon specifically, but does not invalidate US9539218B2 or US10828310B2. Both patents remain enforceable assets that can be asserted against other generic challengers. The early resolution — before claim construction — means no adverse claim-scope rulings were entered that could weaken the patents' position in future disputes.
Patents intact, enforcement preservedBiocon's counterclaims also extinguished with prejudice
Biocon's dismissal with prejudice extends to all counterclaims and defenses it asserted, meaning Biocon cannot re-litigate its invalidity or non-infringement positions against these plaintiffs regarding these patents in federal court. Whether Biocon retains any pathway to market entry for its rivaroxaban ANDA product cannot be determined from the public record, as the specific terms of any agreement between the parties are not disclosed.
Counterclaims closed; ANDA status undisclosedEarly exit signals risk calculus favoured settlement over litigation
Resolution in 136 days — before substantive motion practice — suggests both sides assessed that the cost and uncertainty of full Delaware patent litigation outweighed their respective positions. For other ANDA filers in the rivaroxaban space, this outcome provides no invalidity precedent. For the XARELTO® franchise, the patents remain unchallened at trial, maintaining their deterrent value against further generic entry without licensing arrangements.
No invalidity precedent setFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Bayer AG | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Janssen Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Bayer Pharma AG | Company | Search in Eureka ↗ |
| Co-Plaintiff | Bayer AG | Company | Search in Eureka ↗ |
| Defendant | Biocon Pharma, Ltd. | Company | /Search in Eureka ↗ |
| Co-Defendant | Biocon Pharma, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Biocon Limited | Company | Search in Eureka ↗ |
| Plaintiff counsel | Derek James Fahnestock | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff counsel | Rodger Dallery Smith , II | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Bayer AGSearch in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the rivaroxaban and oral anticoagulant patent space
Forward-looking patent intelligence on the XARELTO® franchise, Bayer and Janssen's formulation filing activity, and Biocon's cardiovascular generics IP posture.
Bayer and Janssen's rivaroxaban patent lifecycle strategy
US10828310B2's later application number (US16/264032) relative to US9539218B2 (US11/883218) is consistent with a continuation-based lifecycle management approach — a pattern common in blockbuster pharmaceutical franchises. Mapping the full family tree of both patents, including pending continuations and divisionals, reveals the remaining runway of XARELTO® formulation exclusivity and where new claims may be issuing.
Continuation strategy — lifecycle IPFiling trends in oral anticoagulant tablet formulation IP
The DOAC sector has seen sustained patent filing activity around dose-form optimization, bioavailability enhancement, and fixed-dose combinations. Tracking recent filings in rivaroxaban, apixaban, and edoxaban formulation space helps R&D teams identify white space and assess freedom to operate for next-generation anticoagulant products and combination therapies.
DOAC formulation filing trendsBiocon's cardiovascular generics patent activity in the US
Biocon's involvement as both defendant and counterclaim asserter in this rivaroxaban ANDA dispute signals active engagement in the branded cardiovascular generics pipeline. Mapping Biocon's US patent filings and ANDA approvals in the cardiovascular and anticoagulant space provides intelligence on where the company may be building proprietary formulation IP beyond pure generic replication.
Biocon cardiovascular IP pipelineAdjacent formulation innovations beyond current XARELTO® claims
The asserted patents focus on rivaroxaban tablet formulations at specific dose strengths. Adjacent white space may exist in modified-release, paediatric dosage forms, novel excipient combinations, or fixed-dose combination products not directly covered by the current Orange Book estate. Identifying claim gaps within the Bayer/Janssen portfolio could inform differentiated formulation R&D strategies.
Rivaroxaban formulation white spaceSimilar ANDA patent disputes: rivaroxaban and DOAC formulation cases
Explore related Hatch-Waxman ANDA challenges in the rivaroxaban and direct oral anticoagulant formulation space filed in Delaware District Court.
What this case signals for the pharmaceutical patent IP landscape
Fast resolution of a branded pharmaceutical ANDA challenge in Delaware carries specific signals for generic entry strategy and patent portfolio management.
No claim construction means no adverse scope rulings for Bayer and Janssen
Early dismissal before claim construction is a meaningful outcome for patent holders. It preserves the full scope of US9539218B2 and US10828310B2 as written, with no judicial narrowing that could be cited by future ANDA challengers or inter partes review petitioners. Companies monitoring these patents should assess their claims in their current, unrestricted form.
Bilateral with-prejudice dismissal raises the bar for Biocon re-entry on these terms
Biocon's counterclaims — including any invalidity positions — were dismissed with prejudice. This forecloses Biocon from re-asserting those specific claims against Bayer/Janssen on these patents in federal district court, a meaningful constraint on Biocon's litigation strategy for rivaroxaban specifically.
Bayer v Biocon — key questions answered
Bayer AG, Bayer Pharma AG, and Janssen Pharmaceuticals asserted US9539218B2 and US10828310B2. Both patents relate to rivaroxaban tablet formulations covering 2.5 mg, 10 mg, 15 mg, and 20 mg dose strengths — the full commercial range of XARELTO®. The defendants were Biocon Pharma Ltd., Biocon Pharma Inc., and Biocon Limited.
The case was dismissed with prejudice. Under a bilateral stipulation filed pursuant to FRCP 41(a)(1) and 41(c), all claims by plaintiffs against Biocon and all counterclaims by Biocon against plaintiffs were dismissed with prejudice. All parties bore their own costs and attorneys' fees. The specific terms underlying the stipulation are not disclosed in the available public record.
No. A dismissal with prejudice ends the litigation between these specific parties but does not constitute an invalidity finding. No claim construction or merits rulings were entered. US9539218B2 and US10828310B2 remain enforceable as issued, with their full claim scope intact. Both patents can still be asserted against other parties.
Biocon's counterclaims and defenses — which would typically include invalidity and non-infringement positions in an ANDA case — were also dismissed with prejudice. This means Biocon cannot re-assert those specific claims against the plaintiff group regarding these patents in federal district court. Whether any commercial or regulatory arrangement underlies the dismissal is not disclosed in the public record.
The case resolved in 136 days — before claim construction proceedings would typically be scheduled in Delaware. This timeline is consistent with an early negotiated resolution, though the specific basis for the agreement is not disclosed in the available record. No motions on the merits appear to have been decided prior to the stipulated dismissal.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.